A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

NCT05426486 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

136

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: ARX788
DRUG: Pyrotinib maleate
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Docetaxel
DRUG: Carboplatin

Sponsor

Caigang Liu